110 related articles for article (PubMed ID: 24371606)
1. Prolonged response to trabectedin in a heavily pretreated patient with metastatic endometrial carcinoma: A case report and literature review.
Meoni G; Cecere FL; Chaib I; Giommoni E; Di Costanzo F
Gynecol Oncol Case Rep; 2011; 2(1):23-5. PubMed ID: 24371606
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
3. Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
Galizia D; Palesandro E; Nuzzo AM; Pignochino Y; Aliberti S; Aglietta M; Grignani G
Oncol Res; 2013; 20(10):483-90. PubMed ID: 24308159
[TBL] [Abstract][Full Text] [Related]
4. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
[TBL] [Abstract][Full Text] [Related]
5. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
[TBL] [Abstract][Full Text] [Related]
6. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Italiano A; Laurand A; Laroche A; Casali P; Sanfilippo R; Le Cesne A; Judson I; Blay JY; Ray-Coquard I; Bui B; Coindre JM; Nieto A; Tercero JC; Jimeno J; Robert J; Pourquier P
Cancer; 2011 Aug; 117(15):3445-56. PubMed ID: 21287534
[TBL] [Abstract][Full Text] [Related]
7. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
8.
Moura DS; Sanchez-Bustos P; Fernandez-Serra A; Lopez-Alvarez M; Mondaza-Hernandez JL; Blanco-Alcaina E; Gavilan-Naranjo A; Martinez-Delgado P; Lacerenza S; Santos-Fernandez P; Carrasco-Garcia I; Hidalgo-Rios S; Gutierrez A; Ramos R; Hindi N; Taron M; Lopez-Guerrero JA; Martin-Broto J
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365979
[TBL] [Abstract][Full Text] [Related]
9. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Adam JP; Boumedien F; Letarte N; Provencher D
Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
[TBL] [Abstract][Full Text] [Related]
10. Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.
Gastaud L; Saâda-Bouzid E; Le Morvan V; Pourquier P; Ianessi A; Thariat J; Italiano A; Thyss A
Onkologie; 2013; 36(11):670-3. PubMed ID: 24192772
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
[TBL] [Abstract][Full Text] [Related]
12. Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience.
Marchetti C; Musella A; Romito A; Vertechy L; Palaia I; Di Donato V; Boccia S; De Felice F; Monti M; Muzii L; Benedetti Panici P
Oncology; 2017; 93(6):359-366. PubMed ID: 28946142
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
14. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Schöffski P; Taron M; Jimeno J; Grosso F; Sanfilipio R; Casali PG; Le Cesne A; Jones RL; Blay JY; Poveda A; Maki RG; Nieto A; Tercero JC; Rosell R
Eur J Cancer; 2011 May; 47(7):1006-12. PubMed ID: 21376569
[TBL] [Abstract][Full Text] [Related]
15. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
16. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
McMeekin DS; Lisyanskaya A; Crispens M; Oza AM; Braly P; Doering D; Bayever E; Michiels B; Markman M
Gynecol Oncol; 2009 Aug; 114(2):288-92. PubMed ID: 19476988
[TBL] [Abstract][Full Text] [Related]
17. Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.
Brunetti AE; Delcuratolo S; Lorusso V; Palermo L; Di Giorgio A; Pisconti S; Silvestris N
Anticancer Res; 2014 Jul; 34(7):3683-8. PubMed ID: 24982387
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
[TBL] [Abstract][Full Text] [Related]
19. Metastatic extraskeletal Ewing's sarcoma treated with trabectedin: A case report.
Hernando-Cubero J; Sanz-Moncasi P; Hernández-García A; Pajares-Bernard I; Martínez-Trufero J
Oncol Lett; 2016 Oct; 12(4):2936-2941. PubMed ID: 27698882
[TBL] [Abstract][Full Text] [Related]
20. Prolonged clinical response to trabectedin in a heavily pretreated patient with advanced uterine leiomyosarcoma: a case report and literature review.
Corrado G; Salutari V; Fuoco G; Lucidi A; Ferrandina G
Gynecol Oncol; 2011 May; 121(2):416-7. PubMed ID: 21324513
[No Abstract] [Full Text] [Related]
[Next] [New Search]
